CompletedNot Applicable

Application and Clinical Evaluation of Longitudinal Chromatic Aberration Technique in Ophthalmology

China21 participantsStarted 2024-06-01

Plain-language summary

Our study aims to delve into the effects of shifting the focal point of blue light from video or text displayed on a terminal screen forward on the axial length of the eye, ocular blood flow, visual fatigue, and visual function, that is, its relationship with Video Display Terminal (VDT) syndrome and myopia. By examining the decoding ability of the adult subjects' retina to the clarity of the signal, we will attempt to develop a novel, non-invasive strategy to curb the elongation of the eyeball associated with myopia. Concurrently, we will also focus on the pathophysiological mechanisms underlying VDT syndrome and explore its potential link to the progression of myopia, providing new scientific evidence for the prevention and treatment of this ocular condition. This research is expected to provide robust support for addressing the global issue of myopia and the health challenges posed by VDT syndrome. Ultimately, by integrating global eye health issues with the challenges brought about by VDT syndrome, we will propose intervention and prevention strategies, offering new insights for the advancement of ophthalmology and public health sectors, thereby promoting visual acuity and ocular health for the population.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Adult population, regardless of gender
. Refractive error is less than or equal to -2.5D and both eyes achieve corrected visual acuity of 0.8 or higher.
. Normal intraocular pressure with no organic pathology.
. No apparent symptoms of dry eye.
. Willing to cooperate to complete all the tests.
. Voluntarily signing the informed consent form.

Exclusion criteria

. Individuals with strabismus and amblyopia exist.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Ocular Fundus Blood Flow

Timeframe: The total duration of the visual task is 50 minutes. Retinal blood flow is measured for each subject at 0 minutes, 25 minutes, and 50 minutes during the visual task, resulting in a

Trial details

NCT IDNCT06449976

SponsorBeijing Tongren Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-30

View on ClinicalTrials.gov More Longitudinal Chromatic Aberration trials